129 related articles for article (PubMed ID: 29727906)
1. Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.
Forst T; Alghdban MK; Fischer A; Weber MM; Voswinkel S; Heise T; Kapitza C; Plum-Mörschel L
Horm Metab Res; 2018 May; 50(5):403-407. PubMed ID: 29727906
[TBL] [Abstract][Full Text] [Related]
2. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
4. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
[TBL] [Abstract][Full Text] [Related]
5. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
[TBL] [Abstract][Full Text] [Related]
6. Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
Forst T; Falk A; Andersen G; Fischer A; Weber MM; Voswinkel S; Heise T; Kapitza C; Plum-Mörschel L
Diabetes Obes Metab; 2017 Apr; 19(4):489-495. PubMed ID: 28009472
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Müller-Wieland D; Kellerer M; Cypryk K; Skripova D; Rohwedder K; Johnsson E; Garcia-Sanchez R; Kurlyandskaya R; Sjöström CD; Jacob S; Seufert J; Dronamraju N; Csomós K
Diabetes Obes Metab; 2018 Nov; 20(11):2598-2607. PubMed ID: 29947099
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C
Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Mathieu C; Herrera Marmolejo M; González González JG; Hansen L; Chen H; Johnsson E; Garcia-Sanchez R; Iqbal N
Diabetes Obes Metab; 2016 Nov; 18(11):1134-1137. PubMed ID: 27385192
[TBL] [Abstract][Full Text] [Related]
11. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
Garnock-Jones KP
Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
Coppenrath VA; Hydery T
Ann Pharmacother; 2018 Jan; 52(1):78-85. PubMed ID: 28884600
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M; Iqbal N; Lu J; Hirshberg B
Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
[TBL] [Abstract][Full Text] [Related]
14. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
15. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
Qin Y; Adams J; Solis-Herrera C; Triplitt C; DeFronzo R; Cersosimo E
Diabetes Care; 2020 Oct; 43(10):2519-2527. PubMed ID: 32694214
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
Tang W; Engman H; Zhu Y; Dayton B; Boulton DW
Clin Ther; 2019 Aug; 41(8):1545-1563. PubMed ID: 31266654
[TBL] [Abstract][Full Text] [Related]
17. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
Daniele G; Tura A; Brocchi A; Saba A; Campi B; Sancho-Bornez V; Dardano A; Del Prato S
Diabetes Care; 2024 Jul; 47(7):1131-1139. PubMed ID: 38652656
[TBL] [Abstract][Full Text] [Related]
18. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
19. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.
Henry RR; Smith SR; Schwartz SL; Mudaliar SR; Deacon CF; Holst JJ; Duan RY; Chen RS; List JF
Diabetes Obes Metab; 2011 Sep; 13(9):850-8. PubMed ID: 21554520
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1303-1316. PubMed ID: 28984487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]